当前位置：
X-MOL 学术
›
Antivir. Ther.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
The outcome of HIV-positive late presenters according to detectable CMV DNA and anti-CMV treatment.
Antiviral Therapy ( IF 1.3 ) Pub Date : 2018-1-27 , DOI: 10.3851/imp3221 Paolo Bigliano 1 , Andrea Calcagno 1 , Anna Lucchini 1 , Sabrina Audagnotto 1 , Chiara Montrucchio 1 , Letizia Marinaro 1 , Chiara Alcantarini 1 , Valeria Ghisetti 2 , Giovanni Di Perri 1 , Stefano Bonora 1
Antiviral Therapy ( IF 1.3 ) Pub Date : 2018-1-27 , DOI: 10.3851/imp3221 Paolo Bigliano 1 , Andrea Calcagno 1 , Anna Lucchini 1 , Sabrina Audagnotto 1 , Chiara Montrucchio 1 , Letizia Marinaro 1 , Chiara Alcantarini 1 , Valeria Ghisetti 2 , Giovanni Di Perri 1 , Stefano Bonora 1
Affiliation
HIV late presenters are at high risk of cytomegalovirus (CMV) reactivation and end-organ disease. CMV viraemia has been associated with poor survival but the effect of anti-CMV treatment has not been studied in this setting.
中文翻译：
根据可检测的CMV DNA和抗CMV治疗，HIV阳性晚期呈报者的预后。
HIV晚期呈报者处于巨细胞病毒（CMV）激活和终末器官疾病的高风险中。CMV病毒血症与不良的生存率相关，但是在这种情况下尚未研究抗CMV治疗的效果。
更新日期：2020-08-21
中文翻译：
根据可检测的CMV DNA和抗CMV治疗，HIV阳性晚期呈报者的预后。
HIV晚期呈报者处于巨细胞病毒（CMV）激活和终末器官疾病的高风险中。CMV病毒血症与不良的生存率相关，但是在这种情况下尚未研究抗CMV治疗的效果。
京公网安备 11010802027423号